Blueberry, combined with probiotics, alleviates non-alcoholic fatty liver disease via IL-22-mediated JAK1/STAT3/BAX signaling (original) (raw)
* Corresponding authors
a Department of Infection, Affiliated Hospital of Guizhou Medical University, No. 28, Guiyang Street, Guiyang 550001, Guizhou, China
E-mail: minglianggy@163.com, 184184239@qq.com, zhoumingyu@qq.com, zhaoxueke@163.com, mbully@163.com
Abstract
Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent diseases worldwide. Blueberry, combined with probiotics (BP), might be a potential candidate for NAFLD treatment, due to its anti-inflammatory and anti-apoptotic properties. Here, we investigated whether the anti-inflammatory cytokine, IL-22, was involved in the therapeutic process of BP, using cell and rat models of NAFLD. Results indicated that BP significantly reduced lipid droplets and triglyceride (TG) accumulation in NAFLD cells. However, when IL-22 was deficient, the lipid droplets and TG content were significantly increased. In vivo, the serum parameters and pathological degree of NAFLD rats were significantly improved by BP, while IL-22 silencing significantly abolished the BP effect. Immunohistochemistry, immunofluorescence, qRT-PCR, and western blotting showed that the NAFLD group expressed significantly lower levels of IL-22, JAK1, and STAT3, and higher levels of BAX, than the normal group. Furthermore, BP significantly elevated the levels of IL-22, JAK1 and STAT3, and reduced the level of BAX in NAFLD, while IL-22 silencing prevented BP from restoring the expression of JAK1, STAT3, and BAX. We conclude that IL-22 is vital for the therapeutic effect of BP, and acts via activation of JAK1/STAT3 signaling and inhibition of the apoptosis factor BAX, which makes IL-22 a promising target for therapy of NAFLD.
This article is Open Access
Please wait while we load your content... Something went wrong. Try again?
Supplementary files
- Supplementary information PDF (295K)
- Supplementary information PDF (92K)
- Supplementary information PDF (81K)
- Supplementary information PDF (85K)
- Supplementary information PDF (104K)
- Supplementary information PDF (98K)
Article information
DOI
https://doi.org/10.1039/C8FO01227J
Article type
Paper
Submitted
27 Jun 2018
Accepted
17 Oct 2018
First published
31 Oct 2018
This article is Open Access
Download Citation
Food Funct., 2018,9, 6298-6306
Permissions
Blueberry, combined with probiotics, alleviates non-alcoholic fatty liver disease via IL-22-mediated JAK1/STAT3/BAX signaling
J. Zhu, M. Zhou, X. Zhao, M. Mu and M. Cheng,Food Funct., 2018, 9, 6298DOI: 10.1039/C8FO01227J
This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.
To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.